31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients

Paolo Fiorina, Roberto Bassi, Chiara Gremizzi, Andrea Vergani, Rossana Caldara, Alessandra Mello, Alessandro Del Maschio, Francesco De Cobelli, Gianluca Perseghin, Antonio Secchi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

31P-magnetic resonance spectroscopy (31P-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether 31P-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by 31P-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ± 0.07, p = 0.03). In contrast, the β-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 ± 0.10 vs. 6 months = 0.89 ± 0.08, ns). The improvement in the β-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized 31P-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.

Original languageEnglish
JournalActa Diabetologica
Volume49
Issue number1 SUPPL.
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Valsartan
Energy Metabolism
Magnetic Resonance Spectroscopy
Phosphates
Kidney
Adenosine Triphosphate
Therapeutics
Netherlands
Albumins
Arterial Pressure

Keywords

  • Angiotensin receptor antagonists
  • Kidney spectroscopy
  • Kidney transplantation

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients. / Fiorina, Paolo; Bassi, Roberto; Gremizzi, Chiara; Vergani, Andrea; Caldara, Rossana; Mello, Alessandra; Del Maschio, Alessandro; De Cobelli, Francesco; Perseghin, Gianluca; Secchi, Antonio.

In: Acta Diabetologica, Vol. 49, No. 1 SUPPL., 12.2012.

Research output: Contribution to journalArticle

@article{31e6e811cd0f4a6e83d2a481f3b6a779,
title = "31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients",
abstract = "31P-magnetic resonance spectroscopy (31P-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether 31P-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by 31P-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ± 0.07, p = 0.03). In contrast, the β-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 ± 0.10 vs. 6 months = 0.89 ± 0.08, ns). The improvement in the β-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized 31P-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.",
keywords = "Angiotensin receptor antagonists, Kidney spectroscopy, Kidney transplantation",
author = "Paolo Fiorina and Roberto Bassi and Chiara Gremizzi and Andrea Vergani and Rossana Caldara and Alessandra Mello and {Del Maschio}, Alessandro and {De Cobelli}, Francesco and Gianluca Perseghin and Antonio Secchi",
year = "2012",
month = "12",
doi = "10.1007/s00592-012-0369-2",
language = "English",
volume = "49",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - 31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients

AU - Fiorina, Paolo

AU - Bassi, Roberto

AU - Gremizzi, Chiara

AU - Vergani, Andrea

AU - Caldara, Rossana

AU - Mello, Alessandra

AU - Del Maschio, Alessandro

AU - De Cobelli, Francesco

AU - Perseghin, Gianluca

AU - Secchi, Antonio

PY - 2012/12

Y1 - 2012/12

N2 - 31P-magnetic resonance spectroscopy (31P-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether 31P-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by 31P-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ± 0.07, p = 0.03). In contrast, the β-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 ± 0.10 vs. 6 months = 0.89 ± 0.08, ns). The improvement in the β-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized 31P-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.

AB - 31P-magnetic resonance spectroscopy (31P-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether 31P-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by 31P-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ± 0.07, p = 0.03). In contrast, the β-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 ± 0.10 vs. 6 months = 0.89 ± 0.08, ns). The improvement in the β-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized 31P-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.

KW - Angiotensin receptor antagonists

KW - Kidney spectroscopy

KW - Kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=84878834465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878834465&partnerID=8YFLogxK

U2 - 10.1007/s00592-012-0369-2

DO - 10.1007/s00592-012-0369-2

M3 - Article

C2 - 22302190

AN - SCOPUS:84878834465

VL - 49

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 1 SUPPL.

ER -